keyword
MENU ▼
Read by QxMD icon Read
search

Inflammatory bowel disease, tnf, adalimumab

keyword
https://www.readbyqxmd.com/read/27931132/guillain-barr%C3%A3-syndrome-during-adalimumab-therapy-for-crohn%C3%A2-s-disease-coincidence-or-consequence
#1
Guilherme Grossi Lopes Cançado, Eduardo Garcia Vilela
We report the case of a 64-year-old patient diagnosed with extensive ileal Crohn´s disease who developed Guillain-Barré syndrome after starting biological therapy with adalimumab. Neurologic involvement associated with inflammatory bowel diseases is recognized as an extra-intestinal manifestation. After the breakthrough of antitumor necrosis factor alpha (anti-TNF-α) agents, an increasing number of cases of acute inflammatory demyelinating polyneuropathies have been reported; however, only one case has been described in a patient with Crohn´s disease...
December 8, 2016: Scandinavian Journal of Gastroenterology
https://www.readbyqxmd.com/read/27920658/isolated-bilateral-gastrocnemius-myositis-in-crohn-disease-successfully-treated-with-adalimumab
#2
Salvatore Vadala di Prampero, Marco Marino, Francesco Toso, Claudio Avellini, Vu Nguyen, Dario Sorrentino
Extraintestinal manifestations are common in inflammatory bowel disease; however, muscular involvement in Crohn disease is rarely reported. We present a case of a 26-year-old male with ileocolonic Crohn disease who developed sudden tenderness in both calves. Doppler ultrasound was negative for deep vein thrombosis. Magnetic resonance imaging of the gastrocnemius muscle showed high intensity signal in the muscle fibers, and muscle biopsy demonstrated nonspecific lymphocytic myositis. Other relevant laboratory results included normal antineutrophil cytoplasmic antibodies and creatine kinase as well as elevated C-reactive protein, erythrocyte sedimentation rate, and anti-Saccharomyces cerevisiae IgG titer...
September 2016: Case Reports in Gastroenterology
https://www.readbyqxmd.com/read/27862107/systematic-review-with-meta-analysis-comparative-efficacy-of-immunosuppressants-and-biologics-for-reducing-hospitalisation-and-surgery-in-crohn-s-disease-and-ulcerative-colitis
#3
REVIEW
E J Mao, G S Hazlewood, G G Kaplan, L Peyrin-Biroulet, A N Ananthakrishnan
INTRODUCTION: Crohn's disease (CD) and ulcerative colitis (UC) have a progressive course leading to hospitalisation and surgery. The ability of existing therapies to alter disease course is not clearly defined. AIM: To investigate the comparative efficacy of currently available inflammatory bowel disease (IBD) therapies to reduce hospitalisation and surgery. METHODS: We conducted a systematic review in MEDLINE/PubMed for randomised controlled trials (RCT) published between January 1980 and May 2016 examining efficacy of biological or immunomodulator therapy in IBD...
January 2017: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/27799888/biologics-for-the-treatment-of-pyoderma-gangrenosum-in-ulcerative-colitis
#4
K Arivarasan, Vaishali Bhardwaj, Sukrit Sud, Sanjeev Sachdeva, Amarender Singh Puri
Pyoderma gangrenosum (PG) is an uncommon extra-intestinal manifestation of inflammatory bowel disease (IBD). Despite limited published literature, biologics have caused a paradigm shift in the management of this difficult-to-treat skin condition. The clinical data and outcomes of three patients with active ulcerative colitis and concurrent PG treated with biologics (infliximab two and adalimumab one) are reviewed in this report. Biologics were added because of the sub-optimal response of the colonic symptoms and skin lesions to parenteral hydrocortisone therapy...
October 2016: Intestinal Research
https://www.readbyqxmd.com/read/27748629/tnf-alpha-antagonist-induced-lupus-on-three-different-agents
#5
Bindu Madhavi Mudduluru, Shalin Shah, Steven Shamah, Arun Swaminath
Tumor necrosis factor alpha (TNF alpha) antagonists are biologic agents used in the management of inflammatory conditions such as rheumatoid arthritis, seronegative spondyloarthropathies and inflammatory bowel disease. These agents have been recently shown to cause a syndrome called anti-TNF induced lupus (ATIL), a rare condition which has similar clinical manifestations to idiopathic systemic lupus erythematosus (SLE). Given that extra-intestinal manifestations of inflammatory bowel disease include arthritis, it can be difficult to separate arthritis due to underlying disease from drug-induced arthritis...
October 17, 2016: Postgraduate Medicine
https://www.readbyqxmd.com/read/27738572/infliximab-associated-psoriasiform-dermatitis-case-report-and-review-of-a-seemingly-paradoxical-inflammatory-response
#6
Tiffany Y Loh, Philip R Cohen
BACKGROUND: Tumor necrosis factor-α (TNF-α) inhibitors, such as infliximab, adalimumab, and certolizumab pegol are effective agents in the treatment of inflammatory bowel disease. Some individuals undergoing anti-TNF-α therapy for Crohn's disease or ulcerative colitis develop psoriasiform lesions. This is a paradoxical finding, as classical psoriasis is known to respond to these agents. PURPOSE: The clinical features of anti-TNF-α-induced psoriatic dermatitis are described...
September 9, 2016: Curēus
https://www.readbyqxmd.com/read/27723166/understanding-the-complications-of-anti-tnf-therapy-in-east-asian-patients-with-inflammatory-bowel-disease
#7
Jae Hee Cheon
Remarkable advances have been made in the treatment of inflammatory bowel disease (IBD) since the introduction of anti-tumor necrosis factor (TNF)-α agents, especially for patients who are refractory to or cannot tolerate conventional therapies. Currently, infliximab, adalimumab, and golimumab are available in the East Asian medical market, and these agents have been shown to be effective for inducing and maintaining long-term remission of IBD. Despite their clinical benefits, anti-TNF therapy can also lead to increased vulnerability to infections, development of autoimmune diseases and malignancy, and decreased immunogenicity of vaccinations...
October 10, 2016: Journal of Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/27688201/do-tumor-necrosis-factor-inhibitors-increase-cancer-risk-in-patients-with-chronic-immune-mediated-inflammatory-disorders
#8
Yuehong Chen, Marcia Friedman, Gang Liu, Atul Deodhar, Cong-Qiu Chu
Inhibition of tumor necrosis factor (TNF) activity has profoundly changed the management of several immune-mediated inflammatory diseases with great benefit for patients. The application of TNF inhibitors (TNFi), however, also brings a new concern, malignancy. We performed a systemic review to collect the studies reporting cancer incidences and risks in TNFi users regardless of indications. TNFi were most frequently used in treating patients with rheumatoid arthritis (RA) and inflammatory bowel diseases (IBD)...
September 26, 2016: Cytokine
https://www.readbyqxmd.com/read/27686143/outcome-of-inflammatory-bowel-disease-patients-treated-with-tnf-%C3%AE-inhibitors-two-year-follow-up
#9
Erika Lehtola, Johanna Haapamäki, Martti A Färkkilä
BACKGROUND: Biological medications, particularly TNF-α inhibitors, are used increasingly for active inflammatory bowel disease (IBD). Even though they are superior to many older medications in achieving remission and mucosal healing, primary nonresponse and loss of response remain significant problems, and a remarkable proportion of patients still need surgery at some point. OBJECTIVE: To study the outcome of IBD patients treated with TNF-α inhibitors, either infliximab or adalimumab, with a two-year follow-up...
December 2016: Scandinavian Journal of Gastroenterology
https://www.readbyqxmd.com/read/27685822/osteosarcoma-in-a-patient-receiving-long-term-tnf-inhibitor-therapy
#10
J Greene, G M O'Kane, D N Carney, E Aherne, G C O'Toole
Patients with inflammatory bowel disease (IBD) have an increased risk of developing malignancy. The use of immunosuppressive therapies and tumour necrosis factor (TNF) inhibitors in these patients may provide a further risk for the development of malignancy. We report the clinical and pathological findings of a high grade osteosarcoma in a patient with Crohns disease receiving TNF inhibitor therapy. In this case, a 32-year old female presented with a painful right knee after receiving maintenance adalimumab for Crohns disease for a period of six years...
2016: Irish Medical Journal
https://www.readbyqxmd.com/read/27665099/cost-effectiveness-of-drug-monitoring-of-anti-tnf-therapy-in-inflammatory-bowel-disease-and-rheumatoid-arthritis-a-systematic-review
#11
Laura Martelli, Pablo Olivera, Xavier Roblin, Alain Attar, Laurent Peyrin-Biroulet
BACKGROUND: Therapeutic drug monitoring (TDM) of anti-TNF is increasingly used to manage inflammatory bowel diseases (IBD) and rheumatoid arthritis (RA). The cost-effectiveness of this strategy is debated. METHODS: All studies comparing the cost-effectiveness of a TDM-based strategy and an empirical dose management of anti-TNF in IBD or RA were screened. Studies were identified through the MEDLINE electronic database (up to July 2016), and annual international meeting abstracts were also manually reviewed...
September 24, 2016: Journal of Gastroenterology
https://www.readbyqxmd.com/read/27663916/psoriasis-induced-by-anti-tumor-necrosis-factor-alpha-agents-a-comprehensive-review-of-the-literature
#12
REVIEW
Fedra Ciccarelli, Massimo De Martinis, Maria Maddalena Sirufo, Lia Ginaldi
Tumor necrosis factor alpha (TNF-α) inhibitors revolutionized the management of patients affected by autoimmune diseases such as inflammatory bowel diseases, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and psoriasis. The biologic agents targeted to block TNF-α such as infliximab, adalimumab, certulizumab pegol, etanercept, and golimumab, have a good safety profile; however, with increasing, broader, and prolonged use, patients could be exposed to an increased risk of adverse reactions including a wide spectrum of dermatological conditions of different etiology and morphology...
August 2016: Acta Dermatovenerologica Croatica: ADC
https://www.readbyqxmd.com/read/27636407/biological-therapy-in-pediatric-inflammatory-bowel-disease-a-systematic-review
#13
Domenico Corica, Claudio Romano
The incidence of inflammatory bowel disease (IBD) has increased steadily worldwide, both in adult and in children; approximately 25% of IBD patients are diagnosed before the age of 18. The natural history of IBD is usually more severe in children than in adults, and can be associated with linear growth impairment, delayed puberty onset, reduced bone mass index, malnutrition, and the need for surgery. Biological therapies, especially blocking tumor necrosis factor-α (TNFα), have radically modified the treatment strategies and disease course of IBD in children...
September 15, 2016: Journal of Clinical Gastroenterology
https://www.readbyqxmd.com/read/27636201/growth-and-adult-height-in-patients-with-crohn-s-disease-treated-with-anti-tumor-necrosis-factor-%C3%AE-antibodies
#14
Sarah Bamberger, Christine Martinez Vinson, Damir Mohamed, Jérôme Viala, Jean-Claude Carel, Jean-Pierre Hugot, Dominique Simon
Inflammation contributes to growth failure associated with inflammatory bowel diseases. Anti-TNFα therapy induces sustained remission and short-term improvements in height velocity and/or height standard deviation score (H-SDS) patients with Crohn's disease. The purpose of this study was to evaluate growth and adult height in patients with Crohn's disease taking maintenance infliximab or adalimumab therapy.This university-hospital based retrospective study included 61 patients, with a median follow-up of 2...
2016: PloS One
https://www.readbyqxmd.com/read/27591675/sarcoidosis-like-lesions-another-paradoxical-reaction-to-anti-tnf-therapy
#15
Amelie Decock, Gert Van Assche, Séverine Vermeire, Wim Wuyts, Marc Ferrante
BACKGROUND: Since the introduction of anti-tumour necrosis factor [TNF] therapy in inflammatory diseases, paradoxical reactions are increasingly being reported. One of these paradoxical reactions is the development of sarcoidosis-like lesions. This presentation is paradoxical since anti-TNF therapy can also be therapeutic in refractory cases of sarcoidosis. METHODS: We report two cases of sarcoidosis-like lesions under anti-TNF therapy. Both were patients with inflammatory bowel disease [IBD], treated successfully with adalimumab...
September 3, 2016: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/27567553/molecular-mechanisms-of-action-of-anti-tnf-%C3%AE-agents-comparison-among-therapeutic-tnf-%C3%AE-antagonists
#16
Hiroki Mitoma, Takahiko Horiuchi, Hiroshi Tsukamoto, Naoyasu Ueda
Tumor necrosis factor (TNF)-α is a potent pro-inflammatory and pathological cytokines in inflammatory diseases such as rheumatoid arthritis and inflammatory bowel diseases. Anti-TNF-α therapy has been established as an efficacious therapeutic strategy in these diseases. In clinical settings, three monoclonal anti-TNF-α full IgG1 antibodies infliximab, adalimumab, and golimumab, PEGylated Fab' fragment of anti-TNF-α antibody certolizumab pegol, extracellular domain of TNF receptor 2/IgG1-Fc fusion protein etanercept, are almost equally effective for rheumatoid arthritis...
August 24, 2016: Cytokine
https://www.readbyqxmd.com/read/27529048/henoch-sch%C3%A3-nlein-purpura-with-adalimumab-therapy-for-ulcerative-colitis-a-case-report-and-review-of-the-literature
#17
Joseph J LaConti, Jean A Donet, Jeong Hee Cho-Vega, Daniel A Sussman, Dana Ascherman, Amar R Deshpande
Tumor necrosis factor-α (TNFα) inhibitor therapy has signified an important milestone in the fight against many rheumatological disorders and inflammatory bowel disease (IBD). Cutaneous adverse events caused by this class of medications are well known but relatively uncommon. Most reactions are mild and rarely warrant treatment withdrawal. Henoch-Schönlein purpura (HSP) is a disease with cutaneous vasculitis, arthritis, and gastrointestinal and renal involvement that is usually seen in children, though the worst complications are typically seen in adults...
2016: Case Reports in Rheumatology
https://www.readbyqxmd.com/read/27508512/a-systematic-review-on-infliximab-and-adalimumab-drug-monitoring-levels-clinical-outcomes-and-assays
#18
Filipa Silva-Ferreira, Joana Afonso, Pedro Pinto-Lopes, Fernando Magro
BACKGROUND: Immunogenicity to therapeutic proteins has been linked to loss of response by a large percentage of patients taking anti-tumor necrosis factor-alpha agents. Drug monitoring can be extremely useful, allowing physicians to adjust the therapeutic scheme individually. This article aims to systematically review the published data with respect to cutoff levels of infliximab (IFX) and adalimumab (ADA) and relate them to the methodology adopted for quantification of IFX and ADA levels and clinical outcomes...
September 2016: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/27461230/from-the-medical-board-of-the-national-psoriasis-foundation-perioperative-management-of-systemic-immunomodulatory-agents-in-patients-with-psoriasis-and-psoriatic-arthritis
#19
REVIEW
Young M Choi, Maya Debbaneh, Jeffrey M Weinberg, Paul S Yamauchi, Abby S Van Voorhees, April W Armstrong, Michael Siegel, Jashin J Wu
Treatment with systemic immunomodulatory agents is indicated for patients with moderate to severe plaque psoriasis and psoriatic arthritis. In these patients, surgery may confer an increased risk of infectious or surgical complications. We conducted a literature review to examine studies addressing the use of methotrexate, cyclosporine, and targeted immunomodulatory agents (tumor necrosis factor-alfa inhibitors, interleukin [IL]-12/23 inhibitors, IL-17 inhibitors) in patients undergoing surgery. We examined 46 total studies; the majority were retrospective studies in patients with rheumatoid arthritis and inflammatory bowel disease...
October 2016: Journal of the American Academy of Dermatology
https://www.readbyqxmd.com/read/27405310/effect-of-anti-tnf-agents-on-postoperative-outcomes-in-inflammatory-bowel-disease-patients-a-single-institution-experience
#20
Chaya Shwaartz, Adam C Fields, Maximiliano Sobrero, Brian D Cohen, Celia M Divino
BACKGROUND: Anti-tumor necrosis factor (TNF) agents have been an integral part in the treatment of inflammatory bowel disease. However, a subset of inflammatory bowel disease patients ultimately requires surgery and up to 30 % of them have undergone treatment with anti-TNF agents. Studies assessing the effect of anti-TNF agents on postoperative outcomes have been inconsistent. The aim of this study is to assess postoperative morbidity in inflammatory bowel disease patients who underwent surgery with anti-TNF therapy prior to surgery...
September 2016: Journal of Gastrointestinal Surgery: Official Journal of the Society for Surgery of the Alimentary Tract
keyword
keyword
24901
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"